This study is for people with HIV-1, a virus that affects the immune system, who are currently taking a regular HIV treatment called Biktarvy (BVY). The study is testing new drugs, GS-1720 and GS-4182, to see if they are safe and work well. There are two parts to the study: Phase 2 lasts 24 weeks and Phase 3 lasts 48 weeks. In Phase 2, the study compares weekly doses of GS-1720/GS-4182 with daily BVY. In Phase 3, it compares weekly fixed-dose tablets of GS-1720/GS-4182 with daily BVY.

Key Points to Consider:

• The study will last either 24 or 48 weeks, depending on the phase.
• Participants must have been taking BVY and have a very low amount of the virus in their blood for at least 24 weeks before starting.
• You cannot join if you've used certain other HIV drugs before or have some specific health conditions or lab results.